ABBV-744 alone only transiently and marginally suppressed MCF-7 p53−/− breast tumor cell growth at 96 and 120 h; inhibitory effects were no longer evident at 144 h (Figure 4A). This evidence concerns the gene TP53 and breast neoplasm.